Summary
Patients with malignant disease may be predisposed to bacterial infections because of neoplastic disruption of normal tissue barriers, exogenous immunosuppressive therapy (drugs with or without radiation), and intrinsic host immune deficits secondary to these diseases. Diminished polymorphonuclear leucocyte numbers or function and impaired humoral immunity are highly correlated with the development of serious bacterial infections. The usual signs and symptoms of infection may be absent or altered in a compromised host.
Therapy must be instituted promptly upon clinical suspicion of bacterial infection, and empirical choices should usually include combinations that are synergistic for likely pathogens based on knowledge of the local predominant flora and susceptibility data. Synergism has most often been demonstrated in combinations that utilise a β-lactam (semisynthetic penicillin or cephalosporin) and an aminoglycoside. Triple drug therapy has not been shown to be advantageous. Monotherapy with third generation cephalosporins, carbapenems, monobactams, or ureidopenicillins has not been proven to offer advantages over 2-drug regimens for these patients.
Granulocytopenic patients who respond to 2-drug therapy but remain neutropenic may need continued treatment until the neutropenia subsides. Those who do not respond and remain febrile with an unclear focus may need to be started on antifungal therapy in addition to the antibacterial agent. The use of oral agents for the prophylaxis of neutropenic patients against bacteraemia remains controversial. If drugs are used, co-trimoxazole and nystatin suspension may be preferable.
Similar content being viewed by others
References
Acar, J.F.; Sabath, L.D. and Ruch, P.A.: Antagonism of the antibacterial action of some penicillins by other penicillins and cephalosporins. Journal of Clinical Investigation 55: 446–453 (1975).
Baehncr, R.L.; Neiburger, R.G.; Johnson, D.E. and Murrmann, S.M.: Transient bactericidal defect of peripheral blood phagocytes from children with acute lymphoblastic leukemia receiving craniospinal irradiation. New England Journal of Medicine 289: 1209–1213 (1973).
Barza, M.: Antimicrobial spectrum, pharmacology, and therapeutic use of antibiotics. Part 2: Penicillins. American Journal of Hospital Pharmacy 34: 57–67 (1977).
Barza. M. and Miao, P.V.W.: Antimicrobial spectrum, pharmacology, and therapeutic use of antibiotics. Part 3: Cephalosporins. American Journal of Hospital Pharmacy 34: 621–629 (1977).
Bender, J.F.; Former, C.L.; Schimpft, S.C.; Grove, W.R.; Hahn, D.M.: Love, L.J. and Wiernik, P.: Comparative auditory toxicity of aminoglycoside antibiotics in leukopenic patients. American Journal of Hospital Pharmacy 36: 1083–1087 (1979).
Bergeron, M.G.; Brusch, J.L.; Barza, M. and Weinstein, L.: Bacterial activity and pharmacology of cefazolin. Antimicrobial Agents and Chemotherapy 4: 396–401 (1973).
Bloomfield, C.D. and Kennedy, B.J.: Cephalothin, carbenicillin and gentamicin combination therapy for febrile patients with acute non-lymphocytic leukemia. Cancer 34: 431–437 (1974).
Bode, F..R.; Pare, J.A. and Fraser, R.G.; Pulmonary diseases in the compromised host: A review of clinical and roentgenographic manifestations in patients with impaired host defense mechanisms. Medicine 53: 255–293 (1974).
Bodey, G.P.: Infections in cancer patients. Cancer Treatment Report 2: 89 (1975).
Bodey, G.P.; Buckley, M.; Sathe, Y.S. and Freireich, E.J.: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 64: 328–340 (1966).
Bodey, G.P.; Grose, W.E. and Keating, M.J.: Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer. Reviews of Infectious Diseases 4: 579–585 (1982).
Bodey, G..P.; Ketchel, S.J. and Rodriguez, V.: A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. American Journal of Medicine 67: 608–616 (1979).
Bodey, G.P. and Rodriguez, V..: Advances in the management of Pseudomonas aeruginosa infections in cancer patients. European Journal of Cancer 9: 435–441 (1973).
Boggs, D.R. and Frei, E. III: Clinical studies of fever and infection in cancer. Cancer 13: 1240–1253 (1960).
Browder, A.A.; Huff, J.W. and Petersdorf, R.G.: The significance of fever in neoplastic disease. Annals of Internal Medicine 55: 932–942 (1961).
Brown, C.H. III: Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrobial Agents and Chemotherapy 7: 652 (1975).
Brown, C.H.; Natelson, E.A.; Bradshaw, W.; Williams, T.W. Jr and Alfrey, C.P. Jr: The hemostatic defect produced by carbenicillin. New England of Medicine 291: 265–270 (1974).
Buchner, L.H. and Schneierson, S.S.: Clinical and laboratory aspects of Listeria monocvtogenes infections with a report of ten cases. American Journal of Medicine 45: 904–921 (1968).
Casazza, A.R.; Duvall, C.P. and Carbone, P.P.: Infection in lymphoma: Histology, treatment, and duration in relation to incidence and survival. Journal of the American Medical Association 197: 710–716 (1966).
Cunha, B.A. and Ristuccia, A.M.: Third generation cephalosporins. Medical Clinics of North America 66: 283–291 (1981).
Dahlgren, J.G.; Anderson, E.T. and Hewitt, W.L.: Gentamicin blood level, a guide to nephrotoxicity. Antimicrobial Agents and Chemotherapy 8: 58–62 (1975).
Desser, R.K. and Ultmann, J.E.: Risk of severe infection in patients with Hodgkin’s disease or lymphoma after diagnostic laparotomy and splenectomy. Annals of Internal Medicine 77: 143–146 (1972).
Dinarello, C.A. and Wolff, S.M.: Molecular basis of fever in humans. American Journal of Medicine 72: 799–813 (1982).
Drusano, G.L.; Schimpff, C. and Hewitt, W.L.: The acylampicillins: Mezlocillin, piperacillin, and azlocillin. Reviews of Infectious Diseases 6: 13–32 (1984).
Dudley, M.N. and Barriere, S.L.: Cefotaxime: Microbiology, pharmacology and clinical use. Clinical Pharmacy 1: 114–124 (1982).
Duprez, P. and Michaux, J.L.; Piperacillin or cefotaxime plus amikacin: Result of empirical antibiotic therapy for febrile episodes in granulocytic patients. Current Chemotherapy and Immunotherapy. Proceedings of the 12th International Congress of Chemotherapy, Florence, Italy, July 19–24 (1981).
Edson, R.S. and Keys, T.F.: The aminoglycosides. Mayo Clinic Proceedings 58: 99–102 (1983).
Eliopoulos, G.M. and Moellering, R.C.: Azlocillin, mezlocillin and piperacillin: New broad-spectrum penicillins. Annals of Internal Medicine 97: 755–760 (1982).
Eron, L.J.; Durrer, F.; Goldberg, R.I. and Poretz, D.M.: N-Formimidoly thienamycin versus moxalactam in the treatment of serious infections. Abstract of paper presented at the 23rd International Congress of Chemotherapy, Las Vegas, Nevada, October 24–26 (1983).
European Organization for Research on Treatment of Cancer — International Antimicrobial Therapy Project Group: Three antibiotic regimens in the treatment of infection in febrile, granulocytopenic patients with cancer. Journal of Infectious Diseases 137: 14–29 (1978).
Fainstein, F.; Bodey, G.P.; McCredie, K.B.; Keating, M.J.; Estey, E.H.; Bolivar, R. and Elting, L: Coagulation abnormalities induced by β-laciam antibiotics in cancer patients. Journal of Infectious Diseases 148: 745–750 (1983).
Faser, D.G.: Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of cefamandole and cefoxitin. American Journal of Hospital Pharmacy 36: 1503–1508 (1979).
Geddes, A.M. and Davey, P.G.: The compromised host and antibacterial treatment. Scandinavian Journal of Infectious Diseases (Suppl. 23): 161–166 (1980).
Gentry, L.O.; Jemsed, J.G. and Natelson, E.A.: Effects of sodium piperacillin on platelet function in normal volunteers. Antimicrobial Agents and Chemotherapy 19: 532–533 (1981).
Guay, D.R.P.: Netilmicin. Drug Intelligence and Clinical Pharmacy 17: 83–91 (1983).
Gurwith, M.J.; Brunton, J.L.; Lank, B.A.; Harding, G.K.M. and Ronald, A.R.: A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. American Journal of Medicine 66: 248–256 (1979).
Hersh, E.M.; Bodey, G.P.; Nies, B.A. and Freireich, E.J.: Causes of death in acute leukemia. Journal of the American Medical Association 193: 105–109(1965).
Hersh, E.M. and Freireich, E.J.: Host defence mechanisms and their modification by cancer chemotherapy; in Busch (Ed.) Methods in Cancer Research, pp. 355–361 (Academic Press, New York 1968).
Higby, DJ.; Yates, J.W., Henderson, M.D. and Holland, J.D.: Filtration leukapharesis for granulocyte transfusion therapy. New England Journal of Medicine 292: 761–766 (1975).
Holmes, K.K.; Clark, H.; Silverblatt, F. and Turck, M.: Emergence of resistance in Pseudomonas during carbenicillin therapy. Antimicrobial Agents and Chemotherapy 8: 391–397 (1969).
Hughes, W.T.; Feldman, S. and Cox, F.: Infectious diseases in children with cancer. Pediatric Clinics of North America 21: 583–615 (1974).
Hughes, W.T.; Kuhn, S.; Chaudhary, S.; Feldman, S.; Verzosa, M.; Aur, R.J.A.; Pratt, G and George, S.L.: Successful chemoprophlyaxis for Pneumocystis carinii pneumonitis. New England Journal of Medicine 297: 1419–1426 (1977).
Inagaki, J.; Rodriguez, V. and Bodey, G.P.: Causes of death in cancer patients. Cancer 33: 568–573 (1974).
Issell, B.F. and Bodey, G.P.: Mezlocillin for treatment of infections in cancer patients. Antimicrobial Agents and Chemotherapy 17: 1008–1013 (1980).
Jick, H.: Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Reviews of Infectious Diseases 4: 426–428 (1982).
Keating, M.J.; Bodey, G.P.; Valdivieso, M. and Rodriguez, V.: A randomized comparative trial of three aminoglycosides — comparison of continuous infusions of gentamicin, amikacin, and sisomicin combined with carbenicillin in the treatment of infeclions in neutropenic patients with malignancies. Medicine 58: 159–169 (1979).
Keating. M.J.: Lawson. R.: Grose, W. and Bodey, G.P.: Combination therapy with ticarcillin and sulfamethoxazole-trimethoprim for infections in patients with cancer. Archives of Internal Medicine 141: 926–930 (1981).
Klastersky. J.: Empiric treatment of infections in neutropenic patients with cancer. Reviews of Infectious Diseases Suppl 6: 521–531 (1983).
Klastersky, J.; DeBusscher, L.; Weerts-Ruhl, D. and Prevost, J.M.: Carbenicillin, cefazolin, amikacin as an empiric therapy for febrile granulocytopenic cancer patients. Cancer Treatment Report 61: 1433–1439 (1977).
Klastersky. J.: Hensgens. C. and DeBusscher, L.: Empiric therapy for cancer patients: Comparative study of ticarcillin-tobramycin. ticarcillin-cephalothin. and cephalothin-tobramycin. Antimicrobial Agents and Chemotherapy 7: 640–645 (1975).
Lamb. D.: Pilney, F.: Kelly, W.D. and Good, R.A.: A comparative study of the incidence of anergy in patients with carcinoma, leukemia, Hodgkin’s disease and other lymphomas. Journal of Immunology 89: 555–558 (1962).
Latos, D.L.; Bryan, C.S. and Stone, W.J.: Carbenicitlin therapy in patients with normal and impaired renal function. Clinical Pharmacology and Therapeutics 17: 692–700 (1975).
Law, D.K.; Dudrick. S.J. and Abdou, N.I.: Immunocompetence of patients with protein-calorie malnutrition. The effects of nutritional repletion. Ann. Intern. Med. 79: 545–550 (1973).
Lawson, R.D. and Baskin, R.C: Ceftizoxime treatment of infection in neutropenic patients with malignancies. Journal of Antimicrobial Chemotherapy Suppl. C: 159–165 (1982).
Lau. W.K.; Young, L.S.; Black. R.E.; Winston, D.J.; Linné, S.R.; Weinstein. R.J. and Hewitt, W.L.: Comparative efficacy and toxicily of amikocin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients. American Journal of Medicine 62: 959–966 (1977).
Louria. D.B.; Hensle. T.; Armstrong, D.; Collins, H.S.; Blevins, A.; Krugman, D. and Buse, M.: Listeriosis complicating malignant disease: A new association. Annals of Internal Medicine 67: 261–281 (1967).
Love, L.J.; Schimpff. S.C; Hahn, D.M.; Young V.M.; Standiford, H.C.; Bender. J.F.; Former, C.L. and Wiernik, P.H.: Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin, or netilmicin in febrile patients with granulocytopenia and cancer. American Journal of Medicine 66: 603–610 (1979).
Love. L.J.; Schimpff, S.C; Schiffner, C.A.. and Wiernik, P.H: Improved prognosis for granulocytopenic patients with Gram-negative rod bacteria. American Journal of Medicine 68: 643–648 (1980).
Lyon, J.A.: Cefoperazone. Drug Intelligence and Clinical Pharmacy 17: 7–11 (1983).
Maki, D.G.; Goldman, D.A, and Rhame, F.S.: Infection control in intravenous therapy. Annals of Internal Medicine 79: 867–887 (1973).
Medical Letter: Ticarcillin. 19: 17–18(1977).
Medical Letter: Antimicrobial prophylaxis and treatment in patients with granulocytopenia. 23 (12): 55–56 (1981).
Meyers. B.R.; Hirschman, S.Z. and Axelrod, J.A.: Current patterns of infection in multiple myeloma. American Journal of Medicine 52: 87–92(1972).
Melikian, V.; Wise, R.; Allum, W.H. and Wells, W.D.: Mezlocillin and gentamicin in the treatment of infections in seriously ill and immunosupressed patients. Journal of Antimicrobial Chemotherapy 7: 657–663 (1981).
Mellin, H.E.; Welling, P.G. and Madsen P.O.: Pharmacokinelics of cefamandole in patients with normal and impaired renal function. Antimicrobial Agents and Chemotherapy 11: 262–266 (1977).
Mirsky, H.S. and Cuttner, J.: Fungal infection in acute leukemia. Cancer 30: 348–352(1972).
Nauseef, W.M. and Maki, D.G.: A study of the value of simple protective isolation in patients with granulocytopenia. New England Journal of Medicine 304: 448–453 (1981).
Noone. P.: Use of antibiotics — aminoglycosides. British Medical Journal 2: 549–552 (1978).
Pizzo. P.A.; Robichaud, K.J.; Gill, F.A.; Witebsky, F.G.; Levine, A.S.: Deisseroth, A.B.; Glaubiger, D.L.; Maclowry, J.D.; Magrath, I.T.; Poplack, D.G. and Simon, R.M.: Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. American Journal of Medicine 67: 194–200 (1979).
Pizzo. P.A.; Robichaud, J.; Gill, F.A. and Witebsky, F.G.: Empiric antibiotic and antifungal therapy in cancer patients with prolonged fever and granulocytopenia. American Journal of Medicine 72: 101–111 (1982).
Polk, R.E.: Moxalactam. Drug Intelligence and Clinical Pharmacy. 16: 104–112 (1982).
Poporad. G.A. and Abrutyn, E.: The third-generation cephalosporins: Cefotaxime. moxalactam, and cefoperazone. Hospital Pharmacy 1458–1465 (1982).
Prolla, J.C. and Kirsner, J.B.: The gastrointestinal lesions and complications of the leukemias. Annals of Internal Medicine 61: 1084–1103 (1964).
Reed, M.D.; Bertino, J.S. Jr; Aroneff, S.C; Speck, W.T. and Blumer. J.L.: Evaluation of moxalactam. Clinical Pharmacy 1: 124–134 (1982).
Remington, J.S. and Schimpff. S.C: Please don’t eat the salads. New England Journal of Medicine 304: 433–434 (1981).
Rubin. R.H. and Swartz, M.N.: Trimethoprim-sulfamethoxazole. New England Journal of Medicine 303: 426–432 (1980).
Russo, J. and Russo, M.E.: Comparative review of two new widespectrum penicillins: Mezlocillin and piperacillin. Clinical Pharmacy 1: 207–216 (1982).
Ryan, J.A. Jr; Abel, R.M.; Abbott, W.M.; Hopkins, C.C.; Chesney, T. McC; Colley, R.; Phillips, K. and Fischer, J.E.: Catheter complications in total parenteral nutrition. A prospective study of 200 consecutive patients. New England Journal of Medicine 290: 757–761 (1974).
Schimpff, S.C; Greene, W.H.; Young, V.M.; Fortner, C.L.; Jepson, L.; Cusack, N.; Block J.B., and Wiernik, P.H.: Infection prevention in acute nonlymphocytic leukemia. Annals of Internal Medicine 82: 351–358 (1975).
Schimpff, S.C.: Satterlee, W.; Young, V.M. and Serpick, A.: Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. New England Journal of Medicine 284: 1061–1065 (1971).
Schimpff, S.C.; Young, V.M.; Greene, W.H.; Vermeulen, G.D.; Moody, M.R. and Wiernik, P.H.: Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Annals of Internal Medicine 77: 707–714 (1972).
Sickles, E.A.; Young, V.M.; Green, W.H. and Wiernik, P.H.: Pneumonia in acute leukemia. Annals of Internal Medicine 79: 528–534 (1973).
Simone. J.V.; Holland, E. and Johnson, W.: Fatalities during remission of childhood leukemia. Blood 39: 759–770 (1972).
Stossel, T.P.: Phagocytosis. New England Journal of Medicine 290: 717–723, 774–780, 833–839 (1974).
Stuart, R.K.; Braine, H.G.; Lietman, P.S.; Saral, R. and Fuller, D.J.: Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. American Journal of Medicine 68: 876–885 (1980).
Tanaka. S.K.; Schwind, R.A.; Minassian, B.F.; Lalama, L; Bonner, D.P. and Sykes, R.B.: Synergistic activity of aztreonamaminoglycoside combinations against antibiotic resistant and susceptible aerobic Gram-negative bacilli. Abstract of paper presented at the 23rd International Congress of Chemotherapy, Las Vegas, Nevada, October 24–26 (1983).
Tattersall, M.H.N.; Spiers, A.S.D. and Darrell, J.H.: Initial therapy with combination of five antibiotics in febrile patients with leukemia and neutropenia. Lancet 1: 162–166 (1972).
Thompson, R.L. and Wright, A.J.: Cephalosporin antibiotics. Mayo Clinic Proceedings 58: 79–87 (1983).
Tjernström, Ö.: Prospective evaluation of vestibular and auditory function in 76 patients treated with netilmicin. Scandinavian Journal of Infectious Diseases Suppl. 23: 122–125 (1980).
Viola, M.V.: Acute leukemia and infection. Journal of the American Medical Association 201: 103–106 (1967).
Wade, J.C. and Schimpff, S.C.: Approaches to therapy of bacterial infections in the granulocytopenic patients; in Klastersky (Ed.) Infections in Cancer Patients, pp. 105–129 (Raven Press, New York 1981).
Wade, J.C; Schimpff, S.C.; Hargadon, M.T.; Fortner, C.L.; Young, V.M. and Wiernik, P.H.: Comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the revention of infections in acute leukemia. New England Journal of Medicine 304: 1057–1061 (1981a).
Wade. J.C.; Schimpff, S.C; Newman, K.A.; Fortner, C.L.; Moody, M.R.; Young, V.M. and Wiernik, P.H.: Potential of mezlocillin as empiric single agent therapy in febrile granulocytopenic cancer patients. Antimicrobial Agentsand Chemotherapy 18: 299–306 (1980).
Wade, J.C.; Schimpff, S.C.; Newman, K.A.; Fortner, C.L.; Standiford, H.C. and Wiernik, P.H.: Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. American Journal of Medicine 71: 983–990 (1981b).
Wade, J.C.; Schimpff, S.C. and Wiernik, P.H.: Antibiotic combination-associated nephrotoxicity in granulocytic patients with cancer. Archives of Internal Medicine 141: 1789–1793 (1981c).
Walzer, P.D.; Perl, D.P.; Krogstad, D.J.; Rawson, P.G. and Schultz, M.G.: Pneumocystis carninii pneumonia in the United States: Epidemiologic, diagnostic, and clinical features. Annals of Internal Medicine 80: 83–93 (1974).
Webel, M.L.; Ritts, R.E. Jr; Taswell, H.F.; Donadio, J.V. Jr and Woods,, J.E.: Cellular immunity after intravenous administration of methylprednisolone. Journal of Laboratory and Clinical Medicine 83: 383–392(1974).
Welling, P.G.; Craig, W.A.; Amidon, G.L. and Kunin, CM.: Pharmacokinetics of cefazolin in normal and uremic subjects.. Clinical Pharmacology and Therapeutics 15: 344–353 (1974).
Winston, D.J.; Ho, W.G. and Gale, R.P.: Prophylactic granulocytic tranfusions during chemotherapy of acute leukemia. Annals of Internal Medicine 94: 616–622 (1981).
Winston, DJ.; Ho, W.G.; Young, L.S.; Hewitt, W.L. and Gale, R.P.: Piperacillin plus amikacin therapy versus carbenicillin plus amikacin and febrile, granulocytopenic patients. Archives of Internal Medicine 142: 1663–1667(1982).
Winston, D.J.; Murphy, W.; Young L.S. and Hewitt, W.L: Piperacillin therapy for serious bacterial infections. American Journal of Medicine 69: 255–261 (1980).
Wolfe, M.S.; Armstrong, D.; Louria, D.B. and Blevins, A.: Salmonellosis in patients with neoplastic disease: A review of 100 episodes at Memorial Cancer Center over a 13-year period. Archives of Internal Medicine 128: 546–554 (1971).
World Health Organization Scientific Group: Cell-mediated immunity and resistance to infection. World Health Organization Technical Report Series No. 519 (1973).
Wright, A.J. and Wilkowske, C.J.: The penicillins. Mayo Clinic Proceedings 58: 21–32 (1983).
Young, L.S.: Gram negative sepsis; in Mandell et al. (Eds.) Principles and Practice of Infectious Diseases, pp. 571–608 (John Wiley and Sons, New York 1979).
Young, L.S.; Myer-Dudnik, D.V.; Hindler, J. and Martin, W.J.: Aminoglycosides in treatment of bacteremic infections in the immunocompromised host. Journal of Antimicrobial Chemotherapy 8 (Suppl. A): 121–132 (1981).
Yu. V.L.: Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Annals of Internal Medicine 94: 784–785 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mayer, K.H., DeTorres, O.H. Current Guidelines on the Use of Antibacterial Drugs in Patients with Malignancies. Drugs 29, 262–279 (1985). https://doi.org/10.2165/00003495-198529030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198529030-00004